1. Home
  2. BTCT vs LGVN Comparison

BTCT vs LGVN Comparison

Compare BTCT & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTCT

BTC Digital Ltd.

SELL

Current Price

$0.56

Market Cap

7.5M

Sector

Real Estate

ML Signal

SELL

Logo Longeveron Inc.

LGVN

Longeveron Inc.

SELL

Current Price

$2.29

Market Cap

7.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BTCT
LGVN
Founded
2006
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
7.8M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
BTCT
LGVN
Price
$0.56
$2.29
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $61.25
AVG Volume (30 Days)
★ 253.5K
90.9K
Earning Date
11-27-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 50.76
EPS
★ N/A
N/A
Revenue
N/A
★ $709,000.00
Revenue This Year
$1.58
$46.15
Revenue Next Year
N/A
$24.63
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.43
$0.48
52 Week High
$2.75
$7.60

Technical Indicators

Market Signals
Indicator
BTCT
LGVN
Relative Strength Index (RSI) 34.27 49.56
Support Level $0.50 $0.65
Resistance Level $1.21 $7.30
Average True Range (ATR) 0.06 0.27
MACD 0.01 0.14
Stochastic Oscillator 4.48 37.17

Price Performance

Historical Comparison
BTCT
LGVN

About BTCT BTC Digital Ltd.

BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: